Sernova Honoured as Member of the “2016 TSX Venture 50” and Ranked #4 in Life Sciences and Clean Technologies. Sernova resides in the top 3% of TSX Venture Exchange Companies in market performance.

TORONTO, Feb. 2, 2016 - TO Health! today announced its evolution and strategy to raise the profile of the Toronto Region Human Health and Sciences (HHS) cluster. The vision of the initiative is to make the Toronto region a Top 5 global health science cluster in the next 10 years.

Rna Diagnostics Inc announced today a new study to investigate RDA as a predictor for chemotherapy efficacy in canine lymphoma in partnership with University of Guelph Institute for Comparative Cancer Investigation and the Mona Campbell Centre for Animal Cancer at the Ontario Veterinary College. This study of canine lymphoma is based on the success of an initial canine lymphoma study completed in 2014.

TORONTO, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Novadaq Technologies Inc. (“NOVADAQ” or the “Company”) (NVDQ) (NDQ.TO), the leading developer and provider of clinically relevant fluorescence imaging solutions for use in surgical and diagnostic procedures, announced today preliminary unaudited revenue for the fourth quarter of 2015 and provided 2016 revenue guidance ahead of its participation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. 

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jan. 18, 2016) - Moseda Technologies Inc. (TSX VENTURE:MSD) ("Moseda" or the "Company"), a technology company focused on developing progressive mobile health (mHealth) and telemedicine solutions for institutional and home healthcare, is pleased to announce that it has appointed industry expert Dr. Lisa Crossley, PhD., P.Eng. as CEO and Director and Mr. Sameet Kanade as President and Chairman of the Board as the Company aims to ramp up its client acquisition strategy.

Proteocyte Diagnostics Inc. today announced the completion of a project enhancing the current version of Straticyte™ and opening up new potential applications. This significant advancement has led to additional Intellectual Property and value creation for the Company.

The United States Environmental Protection Agency has approved Vive Crop Protection's Bifender™ insecticide using Vive's proprietary Allosperse® delivery technology. The product contains bifenthrin, an excellent broad-spectrum insecticide, and is targeted for early-season in-furrow or soil applications.

Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical stage regenerative medicine company, today announced that Dr. Philip Toleikis, Sernova’s President and CEO, will be providing a corporate update at the 8th annual Biotech Showcase Conference in San Francisco, CA, at 4:00 p.m. PST on January 13, 2016 in San Francisco, California.

In a full roster of business development meetings, Dr. Toleikis will also be updating key pharma and institutional audiences on the company's progress and future plans.

Proteocyte Diagnostics Inc. today announced the completion of a project enhancing the current version of Straticyte™ and opening up new potential applications.

Distinguished European consortium awarded approximately $8.5 Million CAD by the European Commission via its Horizon 2020 Program to partner advanced cell based Factor VIII therapy in collaboration with Sernova and its Cell Pouch(TM) device technologies.

For the second year, the Consulate General of Canada in San Francisco and the Consulate of Canada in San Diego are pleased to host the Dose of the Valley program for the life sciences sector. 

The Consulate General of Canada in Chicago successfully partnered in 2015 (testimonials included in our enclosed marketing document for the 2016 program) with the Chicago Innovation Mentors (CIM) to provide a comprehensive mentoring program for three Canadian life science and healthcare entrepreneurs. 
 
It is our pleasure to announce that the program has been renewed for 2016. The Consulate will again be able to funnel three Canadian start-ups through CIM’s mentoring program.